MARKET

CNTX

CNTX

Context Therapeutics Inc
NASDAQ
0.1870
-0.0133
-6.64%
After Hours: 0.1979 +0.0109 +5.83% 19:29 11/10 EST
OPEN
0.1999
PREV CLOSE
0.2003
HIGH
0.2009
LOW
0.1862
VOLUME
725.18K
TURNOVER
--
52 WEEK HIGH
3.620
52 WEEK LOW
0.1800
MARKET CAP
17.18M
P/E (TTM)
-0.3873
1D
5D
1M
3M
1Y
5Y
1D
Context Therapeutics Reports Q3 Results and CTIM-76 Trial Progress
TipRanks · 9h ago
Context Therapeutics GAAP EPS of -$0.08 beats by $0.03
Seeking Alpha · 9h ago
Context Therapeutics reports Q3 EPS (8c), consensus (11c)
TipRanks · 9h ago
Press Release: Context Therapeutics Reports Third -2-
Dow Jones · 9h ago
Press Release: Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress
Dow Jones · 9h ago
Weekly Report: what happened at CNTX last week (1102-1106)?
Weekly Report · 1d ago
CNTX Updates CT-95 Cancer Study as Trial Is Listed as Terminated
TipRanks · 5d ago
Weekly Report: what happened at CNTX last week (1026-1030)?
Weekly Report · 11/02 10:25
More
About CNTX
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company, which is engaged in advancing T cell engaging (TCE) bispecific antibodies (bsAb) for solid tumors. It is building a portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 (CLDN6) x CD3 TCE, CT-95, a Mesothelin (MSLN) x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 (Nectin-4) x CD3 TCE. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors and absent from or expressed at low levels in healthy adult tissues. CT-95 is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane protein overexpressed in approximately 30% of cancers. Nectin-4 is a target for cancer therapy using a traditional antibody-drug conjugate, but it is also associated with certain adverse events, including neuropathy and rash. CT-202 is a pH-dependent TCE that is designed to be preferentially active within the acidic tumor microenvironment.

Webull offers Context Therapeutics Inc stock information, including NASDAQ: CNTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CNTX stock methods without spending real money on the virtual paper trading platform.